ZFuze is an anti-inflammatory, osseoconductive, load-bearing biomaterial, according to a Jan. 14 news release. It’s the first biomaterial of its kind approved by the FDA, and ZFuze has a 93.4% lumbar spinal fusion rate at six months.
The patent protects ZFuze’s Master File for another 17 years, CEO and founder Derrick Johns said in the release.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
